Description: Trastuzumab emtansine is an FDA approved antibody-drug conjugate (ADC) drug for cancer treatment, consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity.

纯度：≥98%

CAS：1018448-65-1